Mebendazole - Medication and Pregnancy KB

Mebendazole

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Akpan, 2018	Nigeria Jan - Dec 2015	All consenting healthy pregnant women (singleton) in their second trimester (14 weeks to 28 weeks) attending antenatal care at the University of Calabar teaching hospital during the study period.	Pregnant women that receive a single 500 mg oral dose of Mebendazole plus a daily iron supplement (60 mg elemental iron) and folic acid.	unexposed, sick Pregnant women that receive a single dose placebo plus a daily iron supplement (60 mg elemental iron) and folic acid.	300 / 260	Study on the efficacy of azole in an obstetrical indication, including the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here.
De Silva, 1999	Sri Lanka 1996 - 1997	All women giving birth at the university obstetric units in the 2 Hospitals.	Babies born to mothers who had taken mebendazole during the current pregnancy.	unexposed (general population or NOS) Babies born to mothers who had not taken any anthelmintic during pregnancy.	5275 / 1737	Study on the efficacy of azole in an obstetrical indication, including the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here.
Diav-Citrin, 2003	Israel 1988 - 1999	Women who contacted (directly or through their health care providers) the Israeli Teratogen Information Service for information about gestational exposure.	Pregnant women who were exposed to mebendazole in pregnancy.	unexposed (general population or NOS) Pregnant women who had been counseled about exposures (ie, medications, low- dose irradiation) not known to be teratogenic or embryofetotoxic.	192 / 192	Most of the women in the cohort were exposed to mebendazole during the first trimester (71.5%) of pregnancy, 21.5% of the women were exposed during the second trimester, and 7.0% of the women were exposed during the third trimester.
Gyorkos, 2006	Peru April - Nov 2003	Pregnant women were eligible to participate in the trial if they were older than 18 years of age, were in their second trimester of pregnancy, lived in a periurban or rural area (did not have water or sanitation facilities in the home), had not taken any anthelminthic treatment in the previous 6 months and gave consent.	Pregnant women recruited in their second trimester and randomized to receive a single oral 500-mg dose of mebendazole (Nemasole).	unexposed, sick Pregnant women recruited in their second trimester and randomized to receive a single of placebo.	522 / 520	Study on the efficacy of azole in an obstetrical indication, including the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here.
Torp-Pedersen (Controls exposed to Pyrviniumn), 2016	Denmark 1997 - 2007	All births in Denmark.	Redemption of a prescription for Mebendazole during pregnancy.	exposed to other treatment, sick Redemption of a prescription for Pyrviniumn during pregnancy.	2567 / 1588
Torp-Pedersen (Controls unexposed, NOS), 2016	Denmark 1997 - 2007	All births in Denmark.	Redemption of a prescription for mebendazole during pregnancy.	unexposed (general population or NOS) No redemption of a prescription for mebendazole or pyrvinium during pregnancy.	2567 / 708982

Case-control studies (cohort)

Study	Country Study period	Case	Control	Sample size	Rmk
Acs, 2005	Hungary 1980 - 1996	Newborn infants with congenital abnormality. Exclusions included some mild congenital abnormalities, minor variants, and congenital abnormality syndromes of Mendelian and chromosomal origin.	Newborn infants without congenital abnormality.	22843 / 38151	Route of administration: only mebendazole oral tablets were available.

master protocol